Advertisement
U.S. markets close in 1 hour 38 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0600+0.0200 (+1.92%)
As of 02:22PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.0400
Open1.2600
Bid1.0500 x 800
Ask1.0600 x 4000
Day's Range0.9000 - 1.1500
52 Week Range0.3450 - 1.2800
Volume24,054,578
Avg. Volume3,905,620
Market Cap271.892M
Beta (5Y Monthly)3.56
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateFeb 26, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OCGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ocugen, Inc.
    BLFS: What does Argus have to say about BLFS?BIOLIFE SOLUTIONS INC has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

    Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024. The event will ta

  • GlobeNewswire

    Ocugen to Present at Pharma Market Research Conference

    MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will give the keynote: Future Innovations in Healthcare: From Dreaming to Community Health at the Pharma Market Research Conference (PMRC) from February 7-8, 2024 in Newark, NJ. “

  • GlobeNewswire

    Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

    MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company’s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments ar